Portfolio
We invest in digital health solutions that improve cancer patient journey, transform pharmaceutical R&D, and shift towards more patient centric healthcare.
In the area of disruptive therapeutic platforms we invest in solutions focused on gene and cell therapies.
Current investments
-
A DTx platform in oncology creating patient engagement and leading positive health outcomes.
More info -
An end-to-end scientific solutions company developing novel digital endpoints from wearable sensor data.
More info -
An AI-based platform for reducing the time and cost of drug development through in silico translational medicine
More info -
Novel ex vivo cell engineering platform for cell therapies
More info -
A start-up in digital therapy for pain and anxiety management
More info -
AI powered digital pathology platform developing biomarkers for pharmaceutical development and precision oncology.
More info -
Real-world patient experience platform for oncology enabling best treatment choices and new therapies
More info -
In silico clinical trials platform. Uses
More info
simulation to reduce the risk of R&D
decisions by predicting the clinical benefits
of new drugs in virtual clinical trials before
human trials begin -
High performance genomics and clinical big data management platform.
More info -
Life-saving detection of sepsis
More info
Host response signature for early identification of sepsis -
Signatures to guide cancer treatment.
Agendia website
Prognostic tests for cancer severity and recurrence.Area of interest
Digital HealthStage
Agendia website
On the market since 2004 (Europe) and 2008 (USA) -
Life science platform helps translate breakthrough science into drugs by providing an incubator and resources for young biotechs
Eclosion websiteArea of interest
Digital HealthStage
Eclosion website
4 portfolio companies, three in clinical stage, one IPO. One merger with a public company
Past investments
-
A leader in the field of digital therapeutics
More info -
Digital therapeutics and patient monitoring tools for oncology
More info -
Point of care turn-key Dx platforms.
Biocartis website
Instruments and cartridges for simple and rapid molecular diagnosticsArea of interest
Digital HealthStage
Biocartis website
Idylla platform and first test launched in September 2014
IPO in April 2015 -
Fusion of Effimune and the Euronext listed OSE Pharma. Immunomodulation in autoimmunity, transplantation, and immuno-oncology
OSE Immuno websiteArea of interest
Digital HealthStage
OSE Immuno website
2 clinical stage programs, several preclinical programs -
PasNas research platform.
ABAC Therapeutics website
First-in-class drugs for precision treatment of MDR gram-negative infections. -
New solutions for MDx pretreatment
Sample preparation technologies for molecular diagnostics
Spinomix websiteArea of interest
Digital HealthStage
Spinomix website
Development phase of magnetic bead handling technology -
Developer of Colox test for blood-based Colorectal Cancer screening
Area of interest
Digital HealthStage
Market entry in Switzerland through collaboration with Novigenix in 2014 -
Focused on active immunotherapy for autoimmune and inflammatory diseases
Initial public offering (IPO) in 2010
Neovacs websiteArea of interest
Digital HealthStage
Neovacs website
Current vaccine development efforts are in Crohn’s disease, rheumatoid arthritis and lupus. In Phase IIb/III
